{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:32:57Z","timestamp":1783603977886,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02567-8","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T17:21:40Z","timestamp":1742664100000},"page":"1677-1682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum levels of rapamycin predict the response of Graves\u2019 orbitopathy to sirolimus"],"prefix":"10.1007","volume":"48","author":[{"given":"Simone","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dal\u00ec Antonia","family":"Ciampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Novella","family":"Maglionico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Posarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-116X","authenticated-orcid":false,"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2567_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","volume":"20","author":"G Lanzolla","year":"2024","unstructured":"Lanzolla G, Marin\u00f2 M, Menconi F (2024) Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol 20:647\u2013660. https:\/\/doi.org\/10.1038\/s41574-024-01016-5","journal-title":"Nat Rev Endocrinol"},{"key":"2567_CR2","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM (2021) The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"2567_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"2567_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Kathleen G, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"issue":"7","key":"2567_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Marin\u00f2 M, Marcocci C, Tanda ML (2022) Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest 45(7):1455\u20131457. https:\/\/doi.org\/10.1007\/s40618-022-01791-w","journal-title":"J Endocrinol Invest"},{"issue":"17","key":"2567_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie T, Lamb YN (2022) Teprotumumab: a review in thyroid eye disease. Drugs 82(17):1663\u20131670. https:\/\/doi.org\/10.1007\/s40265-022-01804-1","journal-title":"Drugs"},{"key":"2567_CR7","unstructured":"Rapamune Prescribing Information. United States Food and Drug Administration. Wyeth Pharmaceuticals, Inc. May 2015. Retrieved 28 May 2016"},{"key":"2567_CR8","unstructured":"Rapamycin. PubChem Compound. National Center for Biotechnology Information. Retrieved 1 Aug 2016"},{"issue":"3 Suppl","key":"2567_CR9","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1016\/s0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35(3 Suppl):7S-14S. https:\/\/doi.org\/10.1016\/s0041-1345(03)00211-2","journal-title":"Transplant Proc"},{"issue":"4","key":"2567_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IOP.0000000000001876","volume":"37","author":"JCP Roos","year":"2021","unstructured":"Roos JCP, Eglitis V, Murthy R (2021) Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease. Ohthalmic Plast Reconstr Surg 37(4):366\u2013371. https:\/\/doi.org\/10.1097\/IOP.0000000000001876","journal-title":"Ohthalmic Plast Reconstr Surg"},{"issue":"1","key":"2567_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12890-018-0626-4","volume":"18","author":"M Molina-Molina","year":"2018","unstructured":"Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatj\u00f2s R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J (2018) Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med 18(1):63. https:\/\/doi.org\/10.1186\/s12890-018-0626-4","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2567_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033626","volume":"7","author":"G Chen","year":"2012","unstructured":"Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS ONE 7(3):e33626. https:\/\/doi.org\/10.1371\/journal.pone.0033626","journal-title":"PLoS ONE"},{"issue":"3","key":"2567_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1055\/s-0032-1311548","volume":"61","author":"SY Yu","year":"2013","unstructured":"Yu SY, Liu L, Li P, Li J (2013) Rapamycin inhibits the mTOR\/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg 61(3):223\u2013228. https:\/\/doi.org\/10.1055\/s-0032-1311548","journal-title":"Thorac Cardiovasc Surg"},{"issue":"11","key":"2567_CR14","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","volume":"45","author":"G Lanzolla","year":"2022","unstructured":"Lanzolla G, Maglionico MN, Comi S, Menconi F, Piaggi P, Posarelli C, Figus M, Marcocci C, Marin\u00f2 M (2022) Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest 45(11):2171\u20132180. https:\/\/doi.org\/10.1007\/s40618-022-01862-y","journal-title":"J Endocrinol Invest"},{"key":"2567_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02470-8[inpress]","author":"S Comi","year":"2024","unstructured":"Comi S, Cosentino G, Lanzolla G, Menconi F, Maglionico MN, Posarelli C, Latrofa F, Rocchi R, Figus M, Santini F, Marin\u00f2 M (2024) Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-024-02470-8[inpress]","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 3","key":"2567_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","volume":"9","author":"LB Kasiske","year":"2009","unstructured":"Kasiske LB, Zeier GM, Craig CJ, Ekberg H, Garvey AC, Green DM, Jha V, Josephson AM, Kiberd AB, Kreis AH, McDonald AR, Newmann MJ, Obrador TG, Chapman RJ, Vincenti GF, Balk ME, Wagner M, Raman G, Earley A, Abariga S (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1-155. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x","journal-title":"Am J Transplant"},{"issue":"3","key":"2567_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-14-0712","volume":"172","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Albano E, Vitti P, Marcocci C, Brunetto M, Marin\u00f2 M (2015) Intravenous glucocorticoid therapy for Graves\u2019 ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172(3):269\u2013276. https:\/\/doi.org\/10.1530\/EJE-14-0712","journal-title":"Eur J Endocrinol"},{"issue":"13","key":"2567_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2174\/1389200221999201027203401","volume":"21","author":"L Lolita","year":"2020","unstructured":"Lolita L, Zheng M, Zhang X, Han Z, Tao J, Fei S, Wang Z, Guo M, Yang H, Ju X, Tan R, Wei JF, Gu M (2020) The genetic polymorphism of CYP3A4 rs 2242480 is associated with sirolimus trough concentrations among adult renal transplant recipients. Curr Drug Metab 21(13):1052\u20131059. https:\/\/doi.org\/10.2174\/1389200221999201027203401","journal-title":"Curr Drug Metab"},{"issue":"14","key":"2567_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/pgs-2021-0083","volume":"22","author":"J Liu","year":"2021","unstructured":"Liu J, Feng D, Kan X, Zheng M, Zhang X, Wang Z, Sun L, Chen H, Gao X, Lu T, Gu M, Tan R, Han Z (2021) Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation. Pharmacogenomics 22(14):903\u2013912. https:\/\/doi.org\/10.2217\/pgs-2021-0083","journal-title":"Pharmacogenomics"},{"issue":"5","key":"2567_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2125.2005.02473.x","volume":"60","author":"C Dansirikul","year":"2005","unstructured":"Dansirikul C, Duffull SB, Morris RG, Tett SE (2005) Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients. Br J Clin Pharmacol 60(5):560\u2013565. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02473.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02567-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02567-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02567-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:31:38Z","timestamp":1753936298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02567-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02567-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Michele Marin\u00f2 is a member of the Journal of Endocrinological Investigation Editorial Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}